<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354302</url>
  </required_header>
  <id_info>
    <org_study_id>MA27B</org_study_id>
    <secondary_id>CAN-NCIC-MA27B</secondary_id>
    <secondary_id>SWOG-NCIC-MA27B</secondary_id>
    <secondary_id>NCCTG-NCIC-MA27B</secondary_id>
    <secondary_id>CAN-NCIC-BONE</secondary_id>
    <secondary_id>CDR0000483099</secondary_id>
    <nct_id>NCT00354302</nct_id>
  </id_info>
  <brief_title>Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27</brief_title>
  <official_title>The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Central Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Learning about the effect of exemestane and anastrozole on bone mineral density in
      postmenopausal women with primary breast cancer may help plan treatment, decrease the risk of
      broken bones, and help patients live more comfortably.

      PURPOSE: This phase III trial is studying bone mineral density in postmenopausal women with
      primary breast cancer who are receiving treatment on clinical trial CAN-NCIC-MA27.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether there is a clinically relevant difference in bone mineral density
           (BMD) at 2 years in postmenopausal women with primary breast cancer (with or without
           osteopenia or osteoporosis) treated with exemestane vs anastrozole on protocol
           CAN-NCIC-MA27.

      OUTLINE: This is a multicenter, companion study. Patients are stratified according to
      baseline bone mineral density (BMD) measurement (T-score* ≥ -2.0 standard deviation [SD] [no
      osteopenia or osteoporosis] vs T-score* &lt; -2.0 SD).

      NOTE: *The lowest of the two T-scores: L1-L4 or total hip

      Blood samples for the identification of bone biomarkers (formation marker: serum
      amino-terminal procollagen 1 extension peptide [P1NP] and resorption marker: serum
      N-telopeptide) are obtained at baseline and at 6 and 12 months. BMD is determined by
      dual-energy x-ray absorptiometry (DEXA) at baseline and then annually for 5 years (or for as
      long as patient is receiving treatment on protocol CAN-NCIC-MA27).

      Patients receive oral calcium and oral cholecalciferol (vitamin D) daily. Patients with
      osteopenia or osteoporosis (stratum II) also receive oral bisphosphonate therapy

      PROJECTED ACCRUAL: A total of 408 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change of bone mineral density (BMD) measured at 2 years (from baseline) in the L1-L4 region of the spine and the hip</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in BMD at 5 years (from baseline)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percentage change in BMD at 1, 3, and 5 years (from baseline)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients without osteopenia or osteoporosis (stratum I) who develop BMD below the absolute threshold for osteopenia (&lt; -2.0 standard deviation below the mean), suffer any osteoporotic fracture, or have an asymptomatic fracture revealed ...</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with osteopenia or osteoporosis (stratum II) who have ≥ 5% improvement of BMD at 2 years post randomization on protocol CAN-NCIC-MA27 and who have clinically apparent osteoporosis-related fracture of the long bones</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of change in bone biomarkers from baseline</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical safety and tolerability of study medications</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">497</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium carbonate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alendronate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium gluconate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dual x-ray absorptometry</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Enrolled in and meets eligibility requirements for protocol CAN-NCIC-MA27

          -  Acceptable quality dual-energy x-ray absorptiometry (DEXA) of the L1-L4
             postero-anterior spine and hip within 12 weeks prior to randomization on protocol
             CAN-NCIC-MA27

          -  Hormone receptor status:

               -  Estrogen receptor- and/or progesterone receptor-positive tumor

        PATIENT CHARACTERISTICS:

          -  Female

          -  Postmenopausal

          -  No malabsorption syndrome

          -  No known cholecalciferol (vitamin D) deficiency, active hyper- or hypoparathyroidism,
             or Paget's disease

          -  No uncontrolled thyroid disease, Cushing's disease, or other pituitary disease

          -  No other bone disease (including osteomalacia or osteogenesis imperfecta)

        PRIOR CONCURRENT THERAPY:

          -  More than 6 months since prior drugs (investigational or not), including
             bisphosphonates, for the prevention of osteoporosis (stratum I)

          -  More than 12 months since prior and no concurrent anticonvulsants

          -  More than 6 months since prior and no concurrent corticosteroids at doses &gt; 5 mg/day
             of prednisone (or equivalent) for &gt; 2 weeks

          -  More than 12 months since prior and no concurrent anabolic steroids

          -  No prior bisphosphonates (stratum II)

          -  No concurrent sodium fluoride at daily doses ≥ 5 mg/day

          -  No long-term (i.e., &gt; 6 months) use of coumarins

          -  No concurrent drugs (investigational or not), including bisphosphonates, for the
             prevention of osteoporosis (for patients with no osteopenia or osteoporosis [stratum
             I])
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul E. Goss, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James N. Ingle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dawn Hershman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge Memorial Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 3G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA-Hopital Du St-Sacrement</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11.</citation>
    <PMID>24636210</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>November 25, 2016</last_update_submitted>
  <last_update_submitted_qc>November 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

